{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T18:51:15Z","timestamp":1786992675126,"version":"build-2736575974"},"reference-count":42,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,9,23]],"date-time":"2024-09-23T00:00:00Z","timestamp":1727049600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003197","name":"Italian Medicines Agency","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003197","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003196","name":"Ministero della Salute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003196","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","journalofinfection.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Infection"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1016\/j.jinf.2024.106294","type":"journal-article","created":{"date-parts":[[2024,9,27]],"date-time":"2024-09-27T16:26:03Z","timestamp":1727454363000},"page":"106294","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Pooled analysis of the MANTICO2 and MONET randomized controlled trials comparing drug efficacy for early treatment of COVID-19 during Omicron waves"],"prefix":"10.1016","volume":"89","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0240-7504","authenticated-orcid":false,"given":"Valentina","family":"Mazzotta","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3907-108X","authenticated-orcid":false,"given":"Fulvia","family":"Mazzaferri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6743-4001","authenticated-orcid":false,"given":"Simone","family":"Lanini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimo","family":"Mirandola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Cozzi Lepri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Vergori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessia","family":"Savoldi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Santoro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-3483-4179","authenticated-orcid":false,"given":"Gaia","family":"Maccarrone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1944-662X","authenticated-orcid":false,"given":"Ilaria","family":"Mastrorosa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4016-4136","authenticated-orcid":false,"given":"Omar","family":"Simonetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federico De","family":"Zottis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emanuele","family":"Nicastri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"Rosini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Rovigo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorenzo","family":"Tavernaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Loredana","family":"Sarmati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlo","family":"Tascini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8182-5896","authenticated-orcid":false,"given":"Enrico","family":"Girardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna Maria","family":"Cattelan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Antinori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evelina","family":"Tacconelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10","key":"10.1016\/j.jinf.2024.106294_bib1","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1016\/S2213-2600(22)00180-1","article-title":"Efficacy and safety of intramuscular administration of tixagevimab-cilgavimab for early outpatient treatment of COVID-19 (TACKLE): a phase 3, randomised, double-blind, placebo-controlled trial","volume":"10","author":"Montgomery","year":"2022","journal-title":"Lancet Respir Med"},{"issue":"21","key":"10.1016\/j.jinf.2024.106294_bib2","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1056\/NEJMoa2107934","article-title":"Early treatment for Covid-19 with SARS-CoV-2 neutralizing antibody sotrovimab","volume":"385","author":"Gupta","year":"2021","journal-title":"N Engl J Med"},{"issue":"15","key":"10.1016\/j.jinf.2024.106294_bib3","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1056\/NEJMoa2118542","article-title":"Oral nirmatrelvir for high-risk, non-hospitalized adults with Covid-19","volume":"386","author":"Hammond","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jinf.2024.106294_bib4","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1056\/NEJMoa2116044","article-title":"Molnupiravir for oral treatment of COVID-19 in non hospitalized patients","volume":"386","author":"Jayk Bernal","year":"2022","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.jinf.2024.106294_bib5","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1056\/NEJMc2207519","article-title":"Efficacy of antibodies and antiviral drugs against Omicron BA.2.12.1, BA.4, and BA.5 subvariants","volume":"387","author":"Takashita","year":"2022","journal-title":"N Engl J Med"},{"issue":"22","key":"10.1016\/j.jinf.2024.106294_bib6","doi-asserted-by":"crossref","first-page":"2094","DOI":"10.1056\/NEJMc2211845","article-title":"In vitro efficacy of antiviral agents against Omicron subvariant BA.4.6","volume":"387","author":"Takashita","year":"2022","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.jinf.2024.106294_bib7","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1056\/NEJMc2214302","article-title":"Efficacy of antiviral agents against Omicron subvariants BQ.1.1 and XBB","volume":"388","author":"Imai","year":"2023","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.jinf.2024.106294_bib8","doi-asserted-by":"crossref","first-page":"e311","DOI":"10.1016\/S1473-3099(22)00311-5","article-title":"Monoclonal antibody therapies against SARS-CoV-2","volume":"22","author":"Focosi","year":"2022","journal-title":"Lancet Infect Dis"},{"issue":"7898","key":"10.1016\/j.jinf.2024.106294_bib9","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1038\/s41586-021-04389-z","article-title":"Considerable escape of SARS-CoV-2 Omicron to antibody neutralization","volume":"602","author":"Planas","year":"2022","journal-title":"Nature"},{"issue":"7898","key":"10.1016\/j.jinf.2024.106294_bib10","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1038\/s41586-021-04385-3","article-title":"Omicron escapes the majority of existing SARS-CoV-2 neutralizing antibodies","volume":"602","author":"Cao","year":"2022","journal-title":"Nature"},{"issue":"7","key":"10.1016\/j.jinf.2024.106294_bib11","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1016\/S1473-3099(22)00365-6","article-title":"Neutralisation sensitivity of SARS-CoV-2 omicron subvariants to therapeutic monoclonal antibodies","volume":"22","author":"Yamasoba","year":"2022","journal-title":"Lancet Infect Dis"},{"issue":"3","key":"10.1016\/j.jinf.2024.106294_bib12","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1080\/17460441.2023.2170348","article-title":"Tixagevimab + cilgavimab against SARS-CoV-2: the preclinical and clinical development and real-world evidence","volume":"18","author":"Convertino","year":"2023","journal-title":"Expert Opin Drug Discov"},{"issue":"4","key":"10.1016\/j.jinf.2024.106294_bib13","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2023.106413","article-title":"Enhanced neutralization escape to therapeutic monoclonal antibodies by SARS-CoV-2 omicron sub-lineages","volume":"26","author":"Touret","year":"2023","journal-title":"iScience"},{"issue":"10","key":"10.1016\/j.jinf.2024.106294_bib14","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1016\/j.medj.2023.07.007","article-title":"Sotrovimab therapy elicits antiviral activities against Omicron BQ.1.1 and XBB.1.5 in sera of immunocompromised patients","volume":"4","author":"Bruel","year":"2023","journal-title":"Med"},{"key":"10.1016\/j.jinf.2024.106294_bib15","unstructured":"U.S. Food and Drug Administration. FDA updates on Sotrovimab emergency use authorization. Available from: \u3008https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/fda-updates-sotrovimab-emergency-use-authorization\u3009. Accessed on 10 May 2024."},{"key":"10.1016\/j.jinf.2024.106294_bib16","unstructured":"European Medicines Agency. COVID-19 medicines. Available from: \u3008https:\/\/www.ema.europa.eu\/en\/human-regulatory-overview\/public-health-threats\/coronavirus-disease-covid-19\/covid-19-medicines#authorised-covid-19-treatments-section\u3009. Accessed on 10 May 2024."},{"key":"10.1016\/j.jinf.2024.106294_bib17","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.79639","article-title":"Exploratory data on the clinical efficacy of monoclonal antibodies against SARS-CoV-2 Omicron variant of concern","volume":"11","author":"Mazzaferri","year":"2022","journal-title":"Elife"},{"key":"10.1016\/j.jinf.2024.106294_bib18","doi-asserted-by":"crossref","first-page":"e192","DOI":"10.1016\/S1473-3099(20)30483-7","article-title":"A minimal common outcome measure set for COVID-19 clinical research","volume":"20","author":"WHO Working Group on the Clinical Characterisation and Management of COVID-19 infection","year":"2020","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.jinf.2024.106294_bib19","doi-asserted-by":"crossref","first-page":"1980","DOI":"10.1007\/s11606-022-07511-7","article-title":"WHO ordinal scale and inflammation risk categories in COVID-19. Comparative study of the severity scales","author":"Rubio-Rivas","year":"2022","journal-title":"J Gen Intern Med"},{"issue":"1","key":"10.1016\/j.jinf.2024.106294_bib20","doi-asserted-by":"crossref","DOI":"10.2196\/31536","article-title":"The easy-to-use SARS-CoV-2 assembler for genome sequencing: development study","volume":"3","author":"Rueca","year":"2022","journal-title":"JMIR Bioinform Biotechnol"},{"key":"10.1016\/j.jinf.2024.106294_bib21","unstructured":"U.S. Department of Health and Human Services. Food and Drug Administration. Assessing COVID-19-related symptoms in outpatient adult and adolescent subjects in clinical trials of drugs and biological products for COVID-19 prevention or treatment. Available from: \u3008https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/assessing-covid-19-related-symptoms-outpatient-adult-and-adolescent-subjects-clinical-trials-drugs\u3009. Accessed 23 March 2024."},{"key":"10.1016\/j.jinf.2024.106294_bib22","doi-asserted-by":"crossref","DOI":"10.1016\/S1473-3099(23)00011-7","article-title":"Real-world use of nirmatrelvir\u2013 ritonavir in outpatients with COVID-19 during the era of omicron variants including BA.4 and BA.5 in Colorado, USA: a retrospective cohort study","author":"Aggarwal","year":"2023","journal-title":"Lancet Infect Dis"},{"issue":"12","key":"10.1016\/j.jinf.2024.106294_bib23","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1016\/S1473-3099(22)00507-2","volume":"22","author":"Wong","year":"2022","journal-title":"Lancet Infect Dis"},{"issue":"10","key":"10.1016\/j.jinf.2024.106294_bib24","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.36678","article-title":"Nirmatrelvir-ritonavir and COVID-19 mortality and hospitalization among patients with vulnerability to COVID-19 complications","volume":"6","author":"Dormuth","year":"2023","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.jinf.2024.106294_bib25","article-title":"Nirmatrelvir and risk of hospital admission or death in adults with covid-19: emulation of a randomized target trial using electronic health records","volume":"381","author":"Xie","year":"2023","journal-title":"BMJ"},{"key":"10.1016\/j.jinf.2024.106294_bib26","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1056\/NEJMoa2204919","article-title":"Nirmatrelvir use and severe Covid-19 outcomes during the omicron surge","volume":"387","author":"Arbel","year":"2022","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.jinf.2024.106294_bib27","doi-asserted-by":"crossref","first-page":"1926","DOI":"10.3390\/vaccines10111926","article-title":"The Delta and Omicron variants of SARS-CoV-2: what we know so far","volume":"10","author":"Chavda","year":"2022","journal-title":"Vaccines"},{"key":"10.1016\/j.jinf.2024.106294_bib28","article-title":"In-hospital mortality during the wild-type, alpha, delta, and omicron SARS-CoV-2 waves: a multinational cohort study in the EuCARE project","volume":"38","author":"Hedberg","year":"2024","journal-title":"Lancet Reg Health Eur"},{"key":"10.1016\/j.jinf.2024.106294_bib29","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2023.104545","article-title":"Emergence and antibody evasion of BQ, BA.2.75 and SARS-CoV-2 recombinant sub-lineages in the face of maturing antibody breadth at the population level","volume":"90","author":"Akerman","year":"2023","journal-title":"EBioMedicine"},{"issue":"2","key":"10.1016\/j.jinf.2024.106294_bib30","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/S1473-3099(22)00831-3","article-title":"Neutralisation sensitivity of the SARS-CoV-2 XBB.1 lineage","volume":"23","author":"Arora","year":"2023","journal-title":"Lancet Infect Dis"},{"issue":"1","key":"10.1016\/j.jinf.2024.106294_bib31","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/S1473-3099(22)00733-2","article-title":"Omicron sublineage BQ.1.1 resistance to monoclonal antibodies","volume":"23","author":"Arora","year":"2023","journal-title":"Lancet Infect Dis"},{"issue":"1","key":"10.1016\/j.jinf.2024.106294_bib32","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1038\/s41467-023-36561-6","article-title":"Resistance of Omicron subvariants BA.2.75.2, BA.4.6, and BQ.1.1 to neutralizing antibodies","volume":"14","author":"Planas","year":"2023","journal-title":"Nat Commun"},{"issue":"17","key":"10.1016\/j.jinf.2024.106294_bib33","doi-asserted-by":"crossref","first-page":"4593","DOI":"10.1016\/j.cell.2021.07.027","article-title":"Tackling COVID-19 with neutralizing monoclonal antibodies","volume":"184","author":"Corti","year":"2021","journal-title":"Cell"},{"issue":"7979","key":"10.1016\/j.jinf.2024.106294_bib34","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1038\/s41586-023-06487-6","article-title":"Neutralization, effector function and immune imprinting of Omicron variants","volume":"621","author":"Addetia","year":"2023","journal-title":"Nature"},{"issue":"4","key":"10.1016\/j.jinf.2024.106294_bib35","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1016\/j.jinf.2023.02.012","article-title":"Real-world effectiveness of molnupiravir, nirmatrelvir-ritonavir, and sotrovimab on preventing hospital admission among higher-risk patients with COVID-19 in Wales: a retrospective cohort study","volume":"86","author":"Evans","year":"2023","journal-title":"J Infect"},{"key":"10.1016\/j.jinf.2024.106294_bib36","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.ijid.2022.09.023","article-title":"Effectiveness of the neutralizing antibody sotrovimab among high-risk patients with mild-to-moderate SARS-CoV-2 in Qatar","volume":"124","author":"Zaqout","year":"2022","journal-title":"Int J Infect Dis"},{"key":"10.1016\/j.jinf.2024.106294_bib37","article-title":"Comparative effectiveness of nirmatrelvir\/ritonavir versus sotrovimab and molnupiravir for preventing severe COVID-19 outcomes in non-hospitalised high-risk patients during Omicron waves: observational cohort study using the OpenSAFELY platform","volume":"34","author":"Zheng","year":"2023","journal-title":"Lancet Reg Health Eur"},{"issue":"7","key":"10.1016\/j.jinf.2024.106294_bib38","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2022.20184","article-title":"Drug interactions with nirmatrelvir-ritonavir in older adults using multiple medications","volume":"5","author":"Ross","year":"2022","journal-title":"JAMA Netw Open"},{"issue":"3","key":"10.1016\/j.jinf.2024.106294_bib39","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1056\/NEJMoa2301425","article-title":"Oral Simnotrelvir for adult patients with mild-to-moderate Covid-19","volume":"390","author":"Cao","year":"2024","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.jinf.2024.106294_bib40","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000033024","article-title":"A phase 2\/3 study of S-217622 in participants with SARS-CoV-2 infection (Phase 3 part)","volume":"102","author":"Yotsuyanagi","year":"2023","journal-title":"Medicine"},{"key":"10.1016\/j.jinf.2024.106294_bib41","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2023.102107","article-title":"Clinical phenotypes and quality of life to define post-COVID-19 syndrome: a cluster analysis of the multinational, prospective ORCHESTRA cohort","volume":"62","author":"Gentilotti","year":"2023","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.jinf.2024.106294_bib42","unstructured":"CoMeCT. The Trial Coordination Board (TCB). Available from: \u3008https:\/\/comectproject.org\/tcb\u3009."}],"container-title":["Journal of Infection"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163445324002287?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163445324002287?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,12,2]],"date-time":"2024-12-02T09:02:52Z","timestamp":1733130172000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0163445324002287"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11]]},"references-count":42,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,11]]}},"alternative-id":["S0163445324002287"],"URL":"https:\/\/doi.org\/10.1016\/j.jinf.2024.106294","relation":{},"ISSN":["0163-4453"],"issn-type":[{"value":"0163-4453","type":"print"}],"subject":[],"published":{"date-parts":[[2024,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pooled analysis of the MANTICO2 and MONET randomized controlled trials comparing drug efficacy for early treatment of COVID-19 during Omicron waves","name":"articletitle","label":"Article Title"},{"value":"Journal of Infection","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jinf.2024.106294","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Ltd on behalf of The British Infection Association.","name":"copyright","label":"Copyright"}],"article-number":"106294"}}